Company news: Sanofi-Aventis, Novartis, Pfizer and Roche
The loss of marketing exclusivity for its bestseller, blood thinner Lovenox, prompted Sanofi-Aventis to trim its earnings outlook.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.